Sugi Predict

Sugi Predict / Compounds / SCHEMBL21232385

SCHEMBL21232385

SCHEMBL21232385

N[C@H](CCC(=O)O)C(=O)OCc1ccccc1

nearest known ligand 0.56

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
▸ LTA4H P09960 6/20 0.56
▸ SLC15A1 P46059 1/20 0.50
▸ HTT P42858 1/20 0.49
▸ ALDH1A1 P00352 3/20 0.49
▸ IDO1 P14902 1/20 0.48
▸ CPA3 P15088 1/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ SLC6A2 P23975 1/20 0.47
▸ SLC6A3 Q01959 1/20 0.47
▸ KMT2A Q03164 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ SLC1A3 P43003 1/20 0.47
▸ SLC1A1 P43005 1/20 0.47
▸ FOLH1 Q04609 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28192478 1.00 LTA4H (0.56) LTA4HSLC15A1HTTALDH1A1IDO1
SCHEMBL124387 1.00 LTA4H (0.56) LTA4HSLC15A1HTTALDH1A1IDO1
SCHEMBL561573 1.00 LTA4H (0.56) LTA4HSLC15A1HTTALDH1A1IDO1
Hydrochloric Acid SCHEMBL29398707 0.98 LTA4H (0.54) LTA4HSLC15A1HTTALDH1A1IDO1
Hydrochloric Acid SCHEMBL15266392 0.98 LTA4H (0.54) LTA4HSLC15A1HTTALDH1A1IDO1
SCHEMBL29720984 0.98 LTA4H (0.54) LTA4HSLC15A1HTTALDH1A1IDO1
Hydrochloric Acid SCHEMBL7263807 0.98 LTA4H (0.54) LTA4HSLC15A1HTTALDH1A1IDO1
Ethylene Glycol SCHEMBL27895455 0.95 LTA4H (0.52) LTA4HSLC15A1HTTALDH1A1IDO1
SCHEMBL27324538 0.93 LTA4H (0.59) LTA4HSLC15A1HTTALDH1A1SLC1A3
Alanine SCHEMBL4410295 0.93 LTA4H (0.50) LTA4HSLC15A1ALDH1A1CPA3SLC1A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118237169-A Flotation process of spodumene mineral 中国恩菲工程技术有限公司 2024-06-25 — — CN claimed
US-12378328-B2 Biohybrid peptidoglycan oligomers NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2025-08-05 — — US disclosed
EP-4529542-A1 AMPHIPHILIC POLY(AMINO ACID) LINEAR BLOCK COPOLYMERS AND NANOPARTICLES THEREOF FOR DRUG DELIVERY APPLICATIONS Nanothera Biosciences, Inc. (US) 2025-04-02 — — EP disclosed
CN-119677795-A Amphiphilic poly (amino acid) linear block copolymers and nanoparticles thereof for drug delivery applications 纳诺瑟拉生物科学股份有限公司 2025-03-21 — — CN disclosed
EP-4425181-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE Bertis Inc (KR) 2024-09-04 — — EP disclosed
CN-118237169-A Flotation process of spodumene mineral 中国恩菲工程技术有限公司 2024-06-25 — — CN disclosed
US-20240011979-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS INC. (KR) 2024-01-11 — — US disclosed
WO-2023227633-A1 AMPHIPHILIC POLY(AMINO ACID) LINEAR BLOCK COPOLYMERS AND NANOPARTICLES THEREOF FOR DRUG DELIVERY APPLICATIONS NANOTHERA BIOSCIENCES, INC. (US) 2023-11-30 — — WO disclosed
EP-4282900-A1 AMPHIPHILIC POLY(AMINO ACID) BLOCK COPOLYMERS AND NANOPARTICLES THEREOF FOR DRUG DELIVERY APPLICATIONS Nanothera Biosciences, Inc. (US) 2023-11-29 — — EP disclosed
US-20230321048-A1 ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS MERSANA THERAPEUTICS, INC. 2023-10-12 — — US disclosed
US-20230321048-A1 ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS MERSANA THERAPEUTICS, INC. 2023-10-12 — — US disclosed
US-20230172910-A1 ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS MERSANA THERAPEUTICS, INC. 2023-06-08 — — US disclosed
US-20230172910-A1 ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS MERSANA THERAPEUTICS, INC. 2023-06-08 — — US disclosed
WO-2023075435-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE 주식회사 베르티스 2023-05-04 — — WO disclosed
US-20220283131-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTES BERTIS CO., LTD. (KR) 2022-09-08 — — US disclosed
US-20220213232-A1 BIOHYBRID PEPTIDOGLYCAN OLIGOMERS NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2022-07-07 — — US disclosed
WO-2022050529-A1 COMPOSITION FOR DETECTING OR MEASURING ANALYTE ㈜베르티스 2022-03-10 — — WO disclosed
US-11230524-B2 Myocyte enhancer factor 2 (MEF2) modulators STANDARD LLC (US) 2022-01-25 — — US disclosed
EP-3197885-B1 HETEROCYCLIC COMPOUNDS AND USE THEREOF NATIONAL HEALTH RES INST (TW) 2020-11-18 — — EP disclosed
US-20190241504-A1 Novel Myocyte Enhancer Factor 2 (MEF2) modulators STANDARD LLC 2019-08-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11230524-B2 Myocyte enhancer factor 2 (MEF2) modulators MEF2D, MYLK2, TNNT2 LTA4H 4634/4885SLC15A1 3579/4885HTT 2174/4885
US-12378328-B2 Biohybrid peptidoglycan oligomers NOD2, DDOST, CD14 LTA4H 353/4885SLC15A1 2532/4885HTT 2326/4885
US-20220213232-A1 BIOHYBRID PEPTIDOGLYCAN OLIGOMERS NOD2, DDOST, CD14 LTA4H 353/4885SLC15A1 2532/4885HTT 2326/4885
US-20190241504-A1 Novel Myocyte Enhancer Factor 2 (MEF2) modulators MEF2D, MYLK2, MYOF LTA4H 4355/4885SLC15A1 3156/4885HTT 3339/4885
US-20230321048-A1 ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS STING1, CGAS, IFNAR1 LTA4H 2497/4885SLC15A1 2830/4885HTT 4328/4885
US-20230172910-A1 ANTIBODY DRUG CONJUGATES COMPRISING STING AGONISTS STING1, CGAS, IFNAR1 LTA4H 2497/4885SLC15A1 2830/4885HTT 4328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.